Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788...
PharmacokineticsHepatic Insufficiency1 moreEvaluate the potential effect of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of BAY 1841788 (ODM-201).
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
Hepatic InsufficiencyThe purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal hepatic function. Information about any side effects that may occur will also be collected. This study will last approximately 28 days, not including screening.
Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure...
Acute on Chronic Liver FailureThe First-In-Man study is a multi-centre, randomised, controlled, study to generate data for the evaluation of safety and performance of DIALIVE Liver Dialysis Device in 24 evaluable patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC).
Cardiox Liver Function Test Pivotal Trial
Hepatic FailureLiver FailurePerformance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum ICG PDR.
Early Liver Support With MARS in Post-hepatectomy Liver Failure
Liver Failure as A Complication of CareThis is a prospective, randomized, open-label, multicentre study involving European centers with experience in the management of PHLF to assess the impact of early liver support with MARS on survival in patients with post-hepatectomy liver failure (PHLF).
The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
Terlipressin Adverse ReactionAscites Hepatic2 morePortal vein hypertension is associated with post-hepatectomy liver failure in patients with liver cirrhosis. Our previous study found that bolus injection of 1 mg terlipressin immediately after hepatectomy decreased portal vein pressure, and post-operative continuous use of terlipressin decreased the amount of abdominal drain. In this multicenter randomized controlled study, we aim to evaluate the effects of terlipressin in the patients who underwent liver resection complicated by portal vein hypertension.
ARAPS Study on Accelerated Liver Regeneration
Liver RegenerationLiver Cancer2 moreLiver resection is the golden standard in the treatment of hepatic malignancies. The size and function of the remnant liver is a major concern. If the future liver remnant (FLR) is below 30 % of the initial liver volume, the risk of post hepatectomy liver insufficiency rises. Several techniques have been developed to increase the size of FLR before liver resection. In this study a new technique ARAPS (portal vein embolization with radio frequency ablation) is compared to portal vein embolization alone for accelerated liver growth in the FLR. This is done in a randomized controlled trial.
The Plasma Diafiltration Therapy of Hepatic Failure
Hepatic FailurePlasma ExchangeAt present, there is no comparative study between the simple plasma exchange and plasma diafiltration (PDF), and no further exploration of optimal plasma dose in PDF treatment. Therefore, this prospective randomized cohort study aims to compare the safety and effectiveness of the tree groups(simple plasma exchange group, conventional PDF treatment group, less plasma PDF treatment group)by collecting SOFA score, 3-month survival rate, MELD score, and the times of artificial liver treatment , blood cell variables, cytokines(e.g. TNFα ), pre- and post-treatment plasma ammonia levels. Thus, it is to provide a safer and more effective artificial liver treatment with less plasma dose.
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
Liver FailureThe purpose of this single center, randomized, control, open-labeled study is to evaluate the effect and safety of RCA versus no anticoagulation for CRRT in patients with liver failure and high risk bleeding.
RL-1 Novel Human-derived Bio-artificial Liver Treatment in Patients of HBV Related ACLF
Hepatitis BAcute-On-Chronic Liver FailureThis study is to investigate the clinical efficacy and safety of RL-1 Novel Human-derived Bio-artificial Liver treatment in patients with Hepatitis b virus related acute-on-chronic liver failure.